Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated.
Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein.
While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001).
Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis.
ClinicalTrials.gov identifier: NCT03584204.
Citation: Queck A, Thomas D, Jansen C, Schreiber Y, Rüschenbaum S, Praktiknjo M, et al. (2019) Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. PLoS ONE 14(10): e0222840. https://doi.org/10.1371/journal.pone.0222840
Editor: Matias A. Avila, University of Navarra School of Medicine and Center for Applied Medical Research (CIMA), SPAIN
Received: July 9, 2019; Accepted: September 8, 2019; Published: October 23, 2019
Copyright: © 2019 Queck et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data may be available upon request as there are ethical restrictions on sharing the data set imposed by the Ethics committee of the University of Bonn, since the data contain potentially identifying patient information. Data access requests may be made to the ethics committee at: Ethik@uni-bonn.de.
Funding: This study was supported by Deutsche Forschungsgemeinschaft SFB TRR57 P18 to Jonel Trebicka; Deutsche Forschungsgemeinschaft CRC1382 to Jonel Trebicka; H2020 European Institute of Innovation and Technology 668031 to Jonel Trebicka; H2020 European Institute of Innovation and Technology 825694 to Jonel Trebicka; H2020 Societal Challenges 731875 to Jonel Trebicka; CELLEX Foundation PREDICT to Jonel Trebicka; Deutsche Forschungsgemeinschaft LA 2806/2-1 to Christian Markus Lange; Deutsche Forschungsgemeinschaft LA 2806/5-1 to Christian Markus Lange; Deutsche Forschungsgemeinschaft SFB 1039/Z01 to Gerd Geisslinger. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: COX, cyclooxygenase; HV, hepatic vein; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PHPG, portal hepatic venous pressure gradient; PV, portal vein; PVT, portal vein thrombosis; TXA2, thromboxane A2; TXB2, thromboxane B2
Cirrhosis has been shown to be a pro- as well as an anticoagulatory condition. Portal vein thrombosis (PVT), in particular, has been described as a sign of progression in disease stage. However, factors related to PVT in cirrhosis have not been elucidated in detail.
Prostanoids are important regulators of the vascular tone, platelet aggregation and vascular remodeling. For biosynthesis of certain prostanoids, arachidonic acid is converted by cyclooxygenases (COXs) to prostaglandin (PG) G2 and subsequently to PGH2. In humans, there are two COX isoforms: COX-1, expressed constitutively, and COX-2, which is inducible. PGH2 is subsequently converted into the prostanoids and thromboxane (TX) depending on specific synthases differentially expressed in each cell type. For example, TXA synthase (TXAS) is mainly expressed in platelets which produce TXA2, a lipid mediator that promotes proliferation of vascular smooth muscle cells and their constriction, platelet activation and aggregation, and finally thrombosis. Importantly, COX-2 and TXAS are induced by various inflammatory stimuli, resulting in a close relationship between inflammation and regulation of the vascular tone and platelet function. Hence, increased production and activity of TXA2 is known to contribute to the pathogenesis of diverse thrombotic arterial diseases, such as stroke or coronary heart disease[6,7]. However, little is known about the role of TXA2 in the portal vein and thrombosis in the portal compartment. One reason for this lack of information is that access to this compartment is difficult. Insertion of transjugular intrahepatic portosystemic stent shunt (TIPS) provides an opportunity to access the portal compartment. According to current guidelines, the major indications for TIPS insertion are treatment and prevention of variceal bleeding and/or intractable or refractory ascites[8,9]. Despite the development of polytetrafluoroethylene (PTFE) covered stents, up to 15% of patients suffer from TIPS dysfunction within the first two years. Especially before the use of PTFE stents, bare metal stent insertion was associated with early TIPS dysfunction, mainly due to pro-thrombotic milieu generation. We hypothesized that prostanoids may contribute to this pro-thrombotic milieu generation. Therefore, blood samples were collected at first puncture of the portal vein during TIPS insertion and certain prostanoids, namely TXB2, a stable metabolite of TXA2, PGD2 and PGE2 were measured.
Patients and methods
Patients and samples
We included eighty-nine patients with diagnosed liver cirrhosis and severe portal hypertension, undergoing TIPS insertion, in our study. Primary outcome was the increase in portal hepatic venous pressure gradient (PHPG) after TIPS insertion as a read-out of pro-thrombotic milieu generation. All patients were treated between August 1996 and August 2003 in the University of Bonn, Department of Internal Medicine I, Germany. Patients, older than 18 years with clinical signs of liver cirrhosis and a multidisciplinary defined indication for TIPS insertion, were included in our trial. Exclusion criteria were the presence of systemic infection, hepatic encephalopathy (higher than grade I), bilirubinemia (higher than 5mg/dl) or arterial pulmonary hypertension. We used bare stents for TIPS insertion (8–10 mm Wallstent, Boston Scientific, MA, USA), as previously described[11,12]. Control angiography was performed after a mean of 14 days. Here, position and function of the stent was evaluated in patients with significant decrease in portal venous flow or TIPS flow (N = 64). The process flow was previously specified as routine in the center’s protocol to optimize TIPS function. During the procedures, portal and hepatic venous pressures were invasively measured by the use of a pressure transducer system (Combitrans, Braun, Melsungen, Germany) and a multichannel monitor (Sirecust, Siemens, Germany). Per definition, the difference between the portal and hepatic venous pressure was named portal hepatic pressure gradient (PHPG). Once, the right branch of the portal vein was cannulated, we harvested blood from portal and hepatic vein in EDTA tubes (N = 89) to obtain material for the analyses of TXB2, PGD2 and PGE2. All TIPS insertions were performed without general anesthesia. After collection of the blood, we centrifuged the samples at 3000 revolutions per minute for 15 minutes at 4°C. Afterwards, plasma samples were stored at minus 80°C. Clinical patient data were recorded at their admission to the study. For the analyses of common blood parameters (e.g. creatinine or bilirubin levels), we used standard biochemical tests. The study protocol passed and has been approved by the local ethics committee of the University of Bonn (029/13). All patients signed and agreed to all procedures as declared in the study protocol. The final manuscript was reviewed by all authors. Access to the study data was ensured and all authors approved the final manuscript.
Liquid chromatography mass spectrometry for prostanoid analysis
Two hundred μL plasma was porcupined with isotopically labeled internal standards (TXB2-d4, PGD2-d4, PGE2-d4), 100 μL EDTA solution (0.15M) and 600 μL ethyl acetate, to quantify levels of thromboxane B2, prostaglandin D2 and E2. Specimens were vortexed, and subsequently centrifuged at 20.000 g for 15 minutes. We removed the organic phase and rerun the extraction by the addition of 600 μL ethyl acetate. After combination of the organic fractions, a sparing stream of nitrogen was used for evaporation at a temperature of 45°C. Reconstitution of the residues was performed by the addition of 50 μL acetonitrile/water/formic acid (20:80:0.0025, v/v/v) and transferred to glass vials. LC-MS/MS analysis was carried out using an Agilent 1290 Infinity LC system (Agilent, Waldbronn, Germany) coupled to the hybrid triple quadrupole linear ion trap mass spectrometer QTRAP 6500+ (Sciex, Darmstadt, Germany) equipped with Turbo V source operating in negative ESI mode. The chromatographic separation was carried out using a Synergi Hydro-RP column (150 × 2 mm, 4 μm particle size and 80 Å pore size; Phenomenex, Aschaffenburg, Germany). A gradient program was employed at a flow rate of 300 μL/min. Mobile phase A was water/formic acid (100:0.0025, v/v) and mobile phase B was acetonitrile/formic acid (100:0.0025, v/v). Seperation of the analytes was performed under gradient conditions within sixteen minutes. The injection volume was 10 μL and the gradient program started with 90% A for 1 min. The mobile phase A was decreased to 60% within 1 min. After 1 min biding, the mobile phase was further decreased to 50% within 1 min and another held for 2 min. Within 2 min, mobile phase A was further decreased to 10% and held for 1 min. In the space of one minute, the initial conditions were restored. The column was re-equilibrated for 6 min. For mass spectrometric, parameters were set as follows: Source temperature 500 °C, ion spray voltage -4500 V, curtain gas 40 psi, nebulizer gas 40 psi and turbo heater gas 60 psi. Both quadrupoles were running at unit resolution. Analyst Software 1.6.3 and Multiquant Software 3.0.2 (both Sciex, Darmstadt, Germany) were used for analysis and quantification. The following precursor-to-product ion transitions were used for quantification: m/z 369.2 → m/z 195.0 for TXB2, m/z 351.2 → m/z 233.3 for PGD2 and m/z 351.2 → m/z 315.0 for PGE2. Peak area of the corresponding internal standard was used for correction of the peak area of each analyte. Calibration curves were constructed using linear regression with 1/x2 weighting. The coefficient of correlation was at least 0.99. Variations in accuracy were less than fifteen percent over the whole range of calibration, except for the lowest limit of quantification, where a variation in accuracy of twenty percent was accepted.
Measurement of lipopolysaccharide levels
Using a commercial enzyme‐linked immunosorbent assay kit (Cusabio), lipopolysaccharide (LPS) serum levels were measured. Therefore, a specific antibody for LPS was precoated onto a microplate, and 100 μL of sample or standards was plated for 2 hours at room temperature. After incubation, samples were read at 450 nm. Values were expressed as picograms per milliliter; intra‐ and inter-assay coefficients of variation were 8% and 10%, respectively.
GraphPad Prism 5 for Windows (GraphPad Software, Inc.) or BIAS® for Windows was used for the performance of statistical analyses. Wilcoxon matched-pairs test was used for paired intra-individual comparisons, namely portal versus hepatic vein prostanoid concentrations. Group differences of unrelated groups were assessed by means of χ2 contingency tables or Wilcoxon-Mann-Whitney U tests, as appropriate. Associations of outcomes with continuous variables were assessed in linear regression models. After univariate analyses, multivariate analyses were performed for significant associations using a P value >0.1. Variables with P >0.1 were discharged from the model. Survival analyses were performed using Cox proportional hazards regression analysis. Correlations were assessed by the use of Spearmen/Kendall rang correlation. P values < 0.05 were considered to be statistically significant.
Baseline characteristics of patients
We included eighty-nine patients with a mean age of fifty-nine, undergoing BMS TIPS insertion, in the study. Refractory ascites (N = 41 patients; 46%) was the major indication for TIPS insertion, followed by secondary prophylaxis of variceal bleeding (N = 36 patients; 40%) and treatment of hepatorenal syndrome (N = 6 patients; 7%). In six patients (7%) indication was presence of both, esophageal variceal bleeding and ascites. Development of cirrhosis was induced in most patients by alcohol abuse (51%), followed by viral hepatitis (7%) and primary biliary cirrhosis (3%). Here, patients presented a mean MELD score of twelve points (range 6–33), and most patients were classified as Child-Pugh B at the time of study inclusion. The mean survival time after TIPS insertion was 770 days. Please find the entire patients characteristics in Table 1.
Prostanoid levels and relation to patient characteristics
Quantification of baseline TXB2 levels during TIPS insertion revealed significantly lower concentrations in the portal than in the hepatic vein (231.2 pg/mL vs. 726.9 pg/mL; P<0.0001). In contrast, concentrations of PGD2 (295.7 pg/mL vs. 169.4 pg/mL; P<0.0001) and of PGE2 (872.6 pg/mL vs. 693.4 pg/mL; P<0.0001) were significantly higher in the portal than in the hepatic vein (Fig 1, Table 1). Since albumin binding of prostanoids has been shown to reduce their bioavailability and activity in patients with liver cirrhosis, we assessed correlations of TXB2, PGD2 and PGE2 with serum albumin concentrations. Here, albumin concentrations correlated inversely with PGD2 and PGE2 concentrations in the portal vein (P = 0.04 each), but neither with portal vein concentrations of TXB2, nor with hepatic vein concentrations of TXB2, PGD2 or PGE2. Patient age did not affect portal or hepatic vein prostanoid levels. Correlation of white blood cell count and portal vein TXB2 levels revealed a significant correlation (P = 0.012). Furthermore, portal and hepatic vein levels of TXB2 correlated with platelet count (PV: P = 0.014; HV: P = 0.002).
Levels of Thromboxane B2 (A), Prostaglandin D2 (B) and Prostaglandin E2 (C) in portal compared to hepatic vein. Wilcoxon matched-pairs signed-ranks test was used to compare differences. P-values <0.05 were considered statistically significant. N = 89.
The severity of liver disease (MELD score) was inversely correlated with the portal as well as the hepatic vein levels of PGD2 and PGE2 (all P<0.0001). Here, creatinine showed a significant inverse correlation with portal and hepatic vein levels of PGD2 and PGE2 and portal vein levels of TXB2 (Table 2).
Association between prostanoid concentrations and portal hepatic venous pressure gradient
The mean portal hepatic venous pressure gradient (PHPG) before TIPS insertion was 20.6 mmHg, and it decreased to a mean of 9 mmHg after TIPS insertion. At control angiography, performed in 64 patients due to significant decrease in portal venous flow or TIPS flow, mean PHPG measurement was 14.6 mmHg (Table 3). Out of 64 patients, 38 had shunt dysfunction due to partial thromboses and received angioplasty. Next, uni- and multivariable regression analysis was performed to identify predictors of PHPG increase after TIPS insertion (Table 4). Of note, baseline TXB2 (P = 0.004) concentrations in the portal vein showed an independent correlation with PHPG increase at short time follow-up. An additional predictor of PHPG increase after TIPS insertion was baseline PHPG (P = 0.001). In contrast, no statistically significant association between portal vein concentrations of PGD2 and PGE2, or hepatic vein concentrations of TXB2, PGD2 and PGE2 was observed.
In a subset of 17 patients, we analyzed portal vein levels of lipopolysaccharide (mean 57.4 pg/ml +/- 9.6pg/ml). Spearmen’s rank correlation did not show significant correlations between portal vein levels of lipopolysaccharide and portal vein levels of PGD2 (R = -0.26; P = 0.31), PGE2 (R = -0.23; P = 0.37), or TXB2 (R = -0.02; P = 0.95).
Predictors of survival after TIPS insertion
COX regression analysis of survival after TIPS insertion revealed baseline creatinine (P<0.0001) concentrations as a negative predictor of survival (S1 Table). In detail, median survival of patients with baseline creatinine concentration ≥1.2 mg/dL was 236 days compared to 820 days in patients with creatinine concentration <1.2 mg/dL (P = 0.0005)(S1 Fig). However, no significant association between prostanoid concentrations in the portal or hepatic vein and patient survival after TIPS insertion was observed.
The major finding of the present study is that concentrations of TXB2 are associated with an increase of PHPG as an indirect sign of thrombogenic potential.
Portal hypertension (PHT) is associated with sequelae, such as ascites, variceal bleeding and hepatorenal syndrome. Besides aggravation of portal hypertension due to cirrhosis, PHT can also be impaired by the development of portal vein thrombosis, which frequently occurs in cirrhosis. These mechanisms are not fully understood. To the best of our knowledge there are no correlations of prevalence of thrombosis with portal pressure. Therefore, this study delivers evidence for a potential mechanism leading to portal hypertension, cirrhosis and PVT.
TXA2 is a potent vasoconstrictor and a major activator of platelets synthesized by TXAS from PGH2, a downstream metabolite of arachidonic acid which is preferentially catalyzed by constitutively expressed COX-1. In turn, TXA2 is highly unstable and rapidly converted into its inactive hydrolysis product TXB2, which is a good surrogate marker of TXAS activity and TXA2 levels. The observation of higher TXB2 concentrations in the hepatic vein compared to the portal vein might be explained by the abundance of COX-1 and COX-2 in liver sinusoidal epithelial cells, which was observed in an animal model of liver cirrhosis. Moreover, high levels of phospholipase A2, an enzyme needed to catalyze the release of arachidonic acid from membrane phospholipids, were observed in the cirrhotic liver of rats[16,17]. However, the experimental evidence about inducible TXB2 release by Kupffer cells in fibrosis with a consequent increase of portal pressure supports our recent finding of elevated TXB2 levels in the human hepatic vein in decompensated liver cirrhosis. At least in animal models, the distribution of these enzymes results in high levels of hepatic TXB2, which is in line with our finding of a post-hepatic increase of TXB2 concentrations. Indeed, aggregation of platelets in cirrhosis might lead to obliteration and parenchymal extinction, which is associated with portal hypertension. This observation was confirmed by the correlation between platelets and TXB2. Also, in the portal vein, TXB2 seems to play a specific role, since it is independently associated with an increase of PHPG and correlated with the white blood count. While in our study, TXB2 concentrations in the portal vein were lower than in the hepatic vein, they must be considered as high, since significantly lower TXB2 concentrations were observed in the systemic circulation of healthy individuals (no data on portal venous TXB2 concentrations have become available to date)[21,22]. Another possible explanation of the TXB2 correlation with increase in PHPG is that TXB2 induced contraction of hepatic stellate cells.
Hence, the association observed here between TXB2 concentrations in the portal vein and increase in PHPG after TIPS insertion appears to be biologically plausible. Furthermore, one may speculate that high levels of TXB2 in the portal vein possibly predispose to the aggravation of PHT and TIPS dysfunction, particularly since it is clearly linked to inflammation, as suggested by the white blood count correlation.
In contrast to TXB2, concentrations of PGE2 and PGD2 were higher in the portal than in the hepatic vein. While we can only speculate on the functional basis of this observation, it is known that the enzymes generating PGD2 and PGE2 are widely distributed in various tissues and, in particular, in inflammatory cells. Therefore, it appears plausible that the high concentrations of PGD2 and PGE2 in the portal vein originate from bacterial translocation, a hallmark of decompensated liver cirrhosis[26,27]. Although PGE2 has rather minor effects on platelets, PGE2 effects on the vascular tone are the opposite of those of TXA2, as PGE2 signaling results in vasodilation. The inverse association, even if not statistically significant, between PGE2 concentration in the portal vein and increase of PHPG after TIPS insertion further supports the potential pathophysiological relevance of our findings.
Interestingly, portal and hepatic vein levels of PGD2 and PGE2 were inversely correlated to the severity of liver diseases as determined by the MELD score. While it is known that PGD2 and PGE2 are secreted by inflammatory cells, here, we did not find a correlation with the white blood count. This can be explained either by immune paralysis due to advanced liver disease with reduced PGD2- and PGE2 release by inflammatory cells or the possibility that other cells are the main producers of PGD2 and PGE2 in this pathological setting.
Evaluating inhibitors of prostanoid synthesis, namely of the TXA2-pathway, for prevention of portal vein thrombosis will be of interest here. These anti-platelet agents not only have anti-thrombotic functions in liver cirrhosis, but also anti-fibrotic and chemoprevention effects inhibiting hepatocellular carcinoma in animal models of liver disease and in clinical association studies[30–33]. On the one hand, non-steroidal anti-inflammatory drugs (NSAID) decrease concentrations of TXA2 by inhibition of COX and may reduce vascular tone in the liver. On the other hand, administration of NSAIDs reduces renal blood flow as well as the glomerular filtration rate in cirrhotic patients with ascites and induces renal failure[34–36]. Moreover, the equilibrium between thrombosis and bleeding is very unstable in liver cirrhosis. Therefore, one should be very careful with systemic drugs in cirrhosis, especially with COX inhibition. Therefore, systemic administration of COX inhibitors is obsolete in cirrhosis and ascites. Since in animal models, COX inhibition seems to be useful in terms of portal hypertension, this liver-specific approach may be considered, as previously shown for Rho-kinase inhibition.
Our study has limitations. We were unable to include a control group of healthy individuals, because no medical interventions allowing for withdrawal of portal or hepatic venous blood were performed in these individuals. Unfortunately, the comparison of peripheral prostanoid levels of healthy controls, compensated and decompensated cirrhotic patients was not focus of this study. Furthermore, we quantified total prostanoid concentrations in the knowledge that albumin binding may also play a role in their bioavailability and activity, in particular in patients with decompensated liver cirrhosis. However, similar results were found when PGD2 and PGE2 were normalized to the respective albumin levels in our study. Moreover, we focused only on the stent thrombosis and other territories were not evaluated. Finally, we can’t exclude the role of the bile leakage on the generation of the thrombogenic milieu and a possible interaction with the prostanoids. Future studies may address all these limitations.
In conclusion, elevated portal venous TXB2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis and offer suitable targets for future therapies.
S1 Table. Cox regression analysis of factors predicting mortality of patients receiving TIPS.
The authors thank S. Bellinghausen and G. Hack for excellent technical assistance and Sabine Dentler for proof reading.
- 1. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. The New England journal of medicine. 2011;365(2):147–56. pmid:21751907
- 2. Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou P-EE, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology (Baltimore, Md). 2015;61(2):660–7.
- 3. Funk C. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (New York, NY). 2001;294(5548):1871–5.
- 4. Ding X, Murray PA. Cellular mechanisms of thromboxane A2-mediated contraction in pulmonary veins. American journal of physiology Lung cellular and molecular physiology. 2005;289(5):L825–33. pmid:15964897
- 5. Bustos M, Coffman T, Saadi S, Platt J. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. The Journal of clinical investigation. 1997;100(5):1150–8. pmid:9276732
- 6. Alshbool FZ, Karim ZA, Espinosa EV, Lin OA, Khasawneh FT. Investigation of a Thromboxane A2 Receptor-Based Vaccine for Managing Thrombogenesis. Journal of the American Heart Association. 2018;7(13).
- 7. Huang S-WW, Kuo H-LL, Hsu M-TT, Tseng YJ, Lin S-WW, Kuo S-CC, et al. A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. Thrombosis and haemostasis. 2016;116(2):285–99. pmid:27173725
- 8. de Franchis R, Faculty BV. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of hepatology. 2015;63(3):743–52. pmid:26047908
- 9. for the of the firstname.lastname@example.org E, for the of the Liver E. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of hepatology. 2018;69(2):406–60. pmid:29653741
- 10. Bureau C, Pagan JC, Layrargues GP, Metivier S, Bellot P, Perreault P, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver international: official journal of the International Association for the Study of the Liver. 2007;27(6):742–7.
- 11. Trebicka J, Krag A, Gansweid S, Schiedermaier P, runk H, Fimmers R, et al. Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. PloS one. 2013;8(12):e83341. pmid:24386183
- 12. Trebicka J, Krag A, Gansweid S, Appenrodt B, Schiedermaier P, Sauerbruch T, et al. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. European journal of gastroenterology & hepatology. 2011;23(12):1218–25.
- 13. Berres M-LL, Asmacher S, Lehmann J, Jansen C, Görtzen J, Klein S, et al. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Journal of hepatology. 2015;62(2):332–9. pmid:25457205
- 14. O’Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nature medicine. 2014;20(5):518–23. pmid:24728410
- 15. Graupera M, March S, Engel P, Rodés J, Bosch J, García-Pagán J-CC. Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. American journal of physiology Gastrointestinal and liver physiology. 2005;288(4):G763–70. pmid:15550559
- 16. Gracia-Sancho J, Laviña B, Rodríguez-Vilarrupla A, García-Calderó H, Bosch J, García-Pagán JC. Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. Journal of hepatology. 2007;47(2):220–7. pmid:17459512
- 17. Rosado E, Rodríguez-Vilarrupla A, Gracia-Sancho J, Monclús M, Bosch J, García-Pagán J-CC. Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats. Journal of cellular and molecular medicine. 2012;16(10):2461–70. pmid:22436078
- 18. Steib CJ, Gerbes AL, Bystron M, den Winkel M, Härtl J, Roggel F, et al. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). Journal of hepatology. 2007;47(2):228–38. pmid:17573142
- 19. Parise L, Venton D, Breton LG. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. The Journal of pharmacology and experimental therapeutics. 1984;228(1):240–4. pmid:6319669
- 20. Stueck AE, Wanless IR. Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis. Hepatology (Baltimore, Md). 2015;61(5):1696–707.
- 21. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vázquez-Fresno R, et al. HMDB 4.0: the human metabolome database for 2018. Nucleic acids research. 2018;46(D1):D608–17. pmid:29140435
- 22. Akimova E. Prostacyclin and thromboxane A2 levels in children and adolescents with an inherited predisposition to coronary heart disease: a family study. Coronary artery disease. 1994;5(9):761–5. pmid:7858766
- 23. Laleman W, Landeghem L, der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology. 2007;132(2):709–19. pmid:17258737
- 24. Urade Y, Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins & other lipid mediators. 2002;68–69:375–82.
- 25. Park JY, Pillinger MH, ramson S. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clinical immunology (Orlando, Fla). 2006;119(3):229–40.
- 26. Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cellular & molecular immunology. 2016;13(3):267–76.
- 27. Queck A, Carnevale R, Uschner FE, Schierwagen R, Klein S, Jansen C, et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut. 2019;
- 28. Friedman EA, Ogletree ML, Haddad EV, Boutaud O. Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease. Thrombosis research. 2015;136(3):493–503. pmid:26077962
- 29. Noor MT, Manoria P. Immune Dysfunction in Cirrhosis. Journal of clinical and translational hepatology. 2017;5(1):50–8. pmid:28507927
- 30. Schwarzkopf K, Bojunga J, Rüschenbaum S, Martinez Y, Mücke MM, Seeger F, et al. Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease. Hepatology communications. 2018;2(12):1601–9. pmid:30556044
- 31. Yoshida S, Ikenaga N, Liu SB, Peng Z-WW, Chung J, Sverdlov DY, et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology. 2014;147(6):1378–92. pmid:25173753
- 32. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nature medicine. 2005;11(11):1167–9. pmid:16258538
- 33. Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. Journal of hepatology. 2013;59(5):1135–8. pmid:23742914
- 34. Elia C, Graupera I, Barreto R, Solà E, Moreira R, Huelin P, et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. Journal of hepatology. 2015;63(3):593–600. pmid:25872166
- 35. Clària J, Kent JD, López-Parra M, Escolar G, Ruiz-Del-Arbol L, Ginès P, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology (Baltimore, Md). 2005;41(3):579–87.
- 36. Ginès P, Arroyo V, Rodés J, Schrier R. Drug-induced renal failure in cirrhosis. Ascites and Renal Dysfunction in Liver Disease. 2005;372.
- 37. Klein S, Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. Journal of hepatology. 2012;57(6):1220–7. pmid:22878469